Healthcare Leaders: Leveraging Data, Emerging MedTech & Collaboration to Meet the Needs of Underserved Communities
Arthi Chandran20:052023
Trials that approve medical products still leave patients of color out
In 2011, African Americans and Hispanic Americans made up 16 and 12 percent of the US population but only 1 and 5 percent of clinical trial patients. Arthi Chandran, a chronic disease epidemiologist leading health economics and reimbursement at Abbott Medical Devices, argues this gap shapes who actually benefits from new technology. If genes do not separate us, what is really driving unequal outcomes, and what can healthcare leaders change?
Learn where trial and design gaps start and the practical steps leaders can take to close them
Arthi Chandran, chronic disease epidemiologist and head of health economics and reimbursement at Abbott Medical Devices, argues that healthcare inequity is driven by social determinants of health rather than biology, and that unrepresentative clinical trials hide how well technologies serve everyone. She outlines practical ways to remove barriers to trial participation, use real-world evidence and patient advocacy, and plan beyond product design so innovations reach underserved communities.
“So I'd like to start today by honoring the fact that we are more similar than we are different.”
“I think we have to know that we can't always solve for inequity using a design of a technology.”
What you will learn
Explain how social determinants of health, rather than genetics, drive disparities in chronic disease and outcomes.
Spot the trial design choices, such as insurance-linked costs and strict protocols, that exclude disadvantaged patients.
Apply practical tactics to diversify study participation, from transportation and home visits to trusted community partners.
Use real-world evidence and patient advocacy to check whether technologies deliver intended outcomes after launch.
Plan support beyond the product itself and discuss bias openly as part of continuous improvement.
Key takeaways from the speaker
Solutions to ensure medical devices and products are designed to support the needs of every person.
Cross-collaboration strategies with payers, providers, stakeholders, regulatory and the healthcare system to have a deeper engagement with clinical teams.
Best practices to develop a deeper engagement with clinical teams to meet your stakeholder’s needs.
Details
Level
Beginner
Format
Talk
Technical depth
Non-technical
For
All career stages
Length
20:05
Published
June 2023
Questions this talk answers
If race is not biological, what explains healthcare disparities between racial groups?
Chandran points to social determinants of health: where people live and work, education, access to healthy food, social support, culture and how they engage with the healthcare system. These are shaped by policy and society and create systemic inequality that disproportionately affects communities of color.
Why are women and people of color underrepresented in medical device trials?
Study costs are often shared by Medicare or commercial insurance, which favors insured patients, and strict protocols exclude people with inflexible work schedules, no caregiver support or no transportation.
How can companies make clinical trials more representative?
By removing access barriers, for example providing transportation, bringing care to patients' homes, improving health literacy, and working with trusted community institutions such as churches, nail salons and barbershops.
What should happen after a technology reaches the market?
Teams should keep learning through real-world evidence, give patients a voice through advocacy, and partner so that asking and investing in these questions becomes the norm.
Can good product design alone solve healthcare inequity?
No. Chandran says design must be paired with plans to do more beyond the product so it actually serves the intended communities.
About this talk
Healthcare products and medical technology are designed to diagnose, treat and support adherence to post-intervention care, ultimately changing the trajectory of one’s health and life experience. To increase affordability and accessibility, healthcare innovations must be backed by data to ensure products support every person. A cross-collaborative approach between clinical teams, researchers, regulatory and stakeholders is essential to satisfy and enhance patient outcomes.
With over 15 years in the healthcare industry, Arthi Chandran designs pathways to success for patients by working with the government, healthcare decision-makers and payers/providers to ensure technology is available to every patient. Using research and evidence-based insights, Arthi articulates the unmet needs of patients to help design services and products to support equity and access.
During the session, Arthi will expand upon how healthcare leaders can better collaborate to ensure data and research drive innovation and healthcare solutions. This will ultimately help create a more equitable healthcare ecosystem ensuring products are designed and available to every community.
The numbers behind trial underrepresentation (64 s)
Reaching communities through churches and barbershops (69 s)
Speaker 1: So good afternoon, and thank you for joining the session. Let's just jump right in. I wanted to start today with a guidance. And that guidance is that to address the needs of underserved, we need to start with understanding. We need to start with the end in mind and kind of work our way backwards, and that starts with questions. So I offer that we need to ask ourselves as well as each other, what makes us different? What drives healthcare inequities?
What role does a fact base and data play in starting to solve for those inequities? And what can we do? Small things, big things, but what can we do to start driving a difference? And today in our session, we won't talk about a checklist of answers and exactly the formula to fix the problem. But rather, I want to leave everyone listening today with an idea, with a number of ideas, spark thinking that hopefully you can carry beyond this session.
So my name is Arti Chandran. I'm a chronic disease epidemiologist and a public health professional. I am also the head of health economics and reimbursement for Abbott medical devices. And Abbott, Abbott's medical device business, it focuses on addressing some of the world's most complex, most prevalent and costly chronic conditions. And those include heart disease, cardiac arrhythmias, diabetes, peripheral arterial disease, pain, as well as movement disorders. And in my role at Abbott, I'm responsible for designing pathways to patient access for our pipeline of innovations. And to do this, I take into consideration a variety of different things. And I look at the world through multiple lenses.
I look at clinical unmet needs. I look at healthcare utility of our innovations. I also look at the environment and I look at healthcare policies that can accelerate access to care, but they can also limit broad access to care. So why? Why am I thinking about things from these different angles? Well, it's because we need to design technologies that are resilient to the diverse pathways of healthcare delivery that we have, not only in the United States, but around the world. We need to do that so that we truly ensure that all of the patients that we look to serve with our technologies actually have an opportunity from benefiting from the innovations that we're creating for them. And so asking questions is a really important part of product development, but it's also a really critical part of making sure that the right patient
gets the right product or solution at the right time. And so in preparation for today's discussion, I started talking to my colleagues. I started engaging individuals, leaders in this industry that touch different phases of product development and really come together to make sure that our ideas turn into products and actually get to our patients and actually get to our patients. And I wanted to know what their perspectives on healthcare inequity and managing care delivery to the underserved looks like.
And in doing so, I was most impacted by a leader in the clinical development organization who pointed out that humans are more similar than we are different, more similar than we are different. And so we really need to take a step back and question what the root cause of inequity actually is. Why are certain populations disadvantaged or disproportionately underserved? So I'd like to start today by honoring the fact that we are more similar than we are different. So if race is not biological, right, if there's no gene that says you're African American or you're Indian, then how do we explain the healthcare disparities that we see?
Why is it that people of color experience illness and experience engagement with healthcare so differently? And so as we look across chronic disease, you can see here that people of color such as African Americans or Hispanic Americans have some of the highest prevalence of disease. And what's not shown here is life expectancy. And for African Americans, the life expectancy is four years lower than for white Americans. And working in the cardiovascular disease space, we know that cardiovascular related mortality is decreasing in the United States, but African Americans still have the highest rate of death. So again, if our genes don't differentiate us, then what is driving that inequity in outcomes?
So going back to my public health roots, I really appreciated where my research started to take me here, which is social determinants of health. So for those of you who might not be familiar with this theory, research shows us that economic and social factors influence patients' healthcare status. They influence our care seeking behaviors. And ultimately, they can influence the risk of negative health outcomes.
And so what are these determinants of health? There are many. They could include where we work on a daily basis. They could include where we live, education, access to education, access to healthy food, the social support systems, our communities, our culture, and even how we engage with the healthcare system. And unlike our genetics, social determinants of health are often driven by policy. They're driven by culture and society.
But what's most important is that these factors can create systemic inequality. And that systemic inequality disproportionately affects communities of color. So why does this matter? How does it relate to data as well as medical technologies and their role in addressing the underserved? Well, we have to, again, start at the end and understand the root cause. What is the root cause of inequity? And what are the right questions?
Are we designing medical technologies or solutions in general that serve the most pressing clinical issues? Probably. I can say that, you know, working in this industry for almost 20 years, it's one of the first questions we ask. Where are the biggest unmet needs and how do we go after them? So if that's the case, then are we asking ourselves, will all the patients that need this particular intervention have an equitable pathway to access?
It's an important question because not all of our patients' environments are created equally. It's an important consideration. What barriers need to be overcome to be able to serve the underserved? Also an important question. So in health care, clinical trials are pivotal. They are central to determining whether a product's safe or whether a product is efficacious. And so we send these off to the FDA.
We do the work. We send them to the FDA. They look at it and they say, yes, this is a safe product to use in humans. However, we know that women and populations of color are systematically underrepresented in these studies. And so that means that although the studies are generalizable on a human level, we don't actually look at the utility of these technologies with the same rigor that we study safety and efficacy.
And so how does this happen? There's a variety of reasons for why this happens. In medical device studies, the cost of that study is often shared by Medicare or by commercial insurance. So that in itself implies that the patient participating in the study most likely going to have insurance. So you automatically start to reduce the proportion of Medicare patients.
You're essentially eliminating the individuals who are financially disadvantaged. But if you start to put together, for example, a hardship program, there are still other factors that can lead to that disproportion of patients in your trials. So, for example, a clinical trial is going to follow a very strict protocol and that patients must comply to that protocol. So that means that you essentially start to eliminate patients that have inflexible work schedules, patients that might not have caregiver support, who might not have access to transportation, and the list goes on.
So without designing studies that are representative, it's hard for us to say that we are truly addressing the needs of a heterogeneous population. And we're also missing that critical piece of evidence that says the way we study impact in this controlled setting is actually what happens in the real world. So there's multiple factors here that we can do better at.
And that latter piece is really what payers are looking for, right? But healthcare systems are investing in technologies that we believe will make a difference in the real world. So why aren't we spending an equal amount of dollars to understand whether we're actually hitting that outcome? It's an opportunity. And so here I just want to illustrate that, you know, although this data is older, I feel like it really tells a good story.
You can see that clinical trials have historically not represented the diversity of the U.S. population. And in 2011, we see that African Americans and Hispanic Americans made up 16 and 12% of the total population, respectively. But you can see that they only make up 1 and 5% of the patients in U.S. clinical trials. So think about that.
Since 2011, how many therapies and technologies are not being evaluated on all populations? So here, more recently, you see work done by the FDA, and they looked at the 53 new drugs that were approved in 2020. And that represented 32,000 patients, but 75% of them were white. So this reinforces that disparity in clinical trial participation. And, you know, we saw this recently in our COVID studies.
But understanding the population that you serve, their unmet needs, and the way they seek care is really fundamental to ensuring that we're able to get our product to them, and that they are actually getting the positive health outcomes that we intend to achieve. So we've laid out the challenge now. So let's get into opportunities. And we can start with clinical trials.
There, you know, there's a ton that we can do to improve upon diverse patient engagement with clinical programs. And again, it starts with those social determinants of health. Let's start removing those barriers to access to these studies. And it can be as simple as providing transportation to your trial site, bringing care to a patient's home, education. And I think health literacy and breaking down cultural barriers that have, you know, been put up for a variety of reasons.
Not everybody's experience with the healthcare system is the same. And there are communities who may not want to participate in research for a variety of different reasons. Websites might be helpful, but they are not the only way to engage with communities. Working with institutions within communities like churches and, you know, trusted partners within the community, whether it's a nail salon or a barber shop.
Those are all options and they require work. They require creative thinking, but they're all ways in which we can start to bridge the divide. But moving beyond the clinical programs, we have to keep learning. We should be using real world evidence to really see how patients are engaging with new technologies so that we can really identify and eliminate barriers to access and start to ensure that people are benefiting.
And again, in the ways that we intend, we need to give patients a voice. Patient advocacy is an incredibly powerful tool. Helping patients articulate what their needs are very specifically. And helping us understand where there are populations that are underserved by our technologies. We also need to partner. It can't just be one individual, one group that's asking these questions, but we need to make it a norm.
Making sure that all of us are asking these questions, answering these questions, and then subsequently investing in addressing these questions so that we can start to make incremental movement forward. And so what does good look like? What happens when we start to do these things right and we start to do them more often? Well, you know, I think just by understanding the people that we are trying to serve better and the diversity of the people that we are trying to serve better, the way they engage with their health care systems, these social determinants that govern the way you and I engage with the health care system.
It allows us to do them. It allows us to be more targeted in how we support our patients, but that volume of information we collect by collectively thinking differently will allow us to systematically identify things that we should constantly be solving for that we're not solving for today. So we will learn together by asking these questions and we'll start to see that our evidence, whether it's clinical evidence or whether it's real world data that we're collecting, it's going to be more representative and we're going to have information that validates each other and creating really a network of learning.
that allows us to solution for the individuals who today are underserved and hopefully tomorrow are not and that's where our next gen health care is going to be impacted right so if we start doing these things right, we're going to start to improve the solutions that we bring to the table, but also how we bring them to the table.
And those are the types of things. And those are the types of things that are going to start to be more measurable. And so, you know, I think in terms of takeaways here, I believe that these takeaways are true regardless of the type of product or solution that we're actually bringing to the marketplace. One just understanding your customer understanding who we are trying to serve and making sure that it's a representative sample of who we're trying to serve.
I think biases are always going to exist. They're always going to exist in our methods and so it's just it's the nature of the research we do it's a nature of our systems today. So we shouldn't be afraid to talk about it. We should be open. We should have an open dialogue around bias and identify ways to compensate for that bias.
And by doing that, we will make incremental improvements towards a better outcome. I think we have to know that we can't always solve for inequity using a design of a technology. So we have to think about design plus we have to plan to do more beyond the product to make sure that our product is actually serving the population, the communities that we want to serve.
And I think one thing that we can all rely on our count on is continuous improvement. We should plan on it. We should plan on continuous improvement and always asking these questions and always improving the way we engage. So I offer you these things. I hope that you do walk away from this session with new ideas, something to chew on, but feel free to reach out to me with any questions or comments if you want to continue this discussion.
Thank you.
Transcribed automatically; names checked against the speaker record. Select a time to jump there.
Article based on this talk
Why medical innovation fails underserved patients, and how better evidence can fix it
Arthi Chandran traces healthcare inequity to social determinants and unrepresentative trials, then lays out practical ways for leaders to close the gap.
In short
Healthcare inequity is not explained by biology, argues Arthi Chandran, but by social and economic factors that also shape who takes part in clinical trials. Because women and people of color are systematically underrepresented in studies, the industry knows far less about how well its technologies work for them in the real world. Her answer is to ask better questions early, remove barriers to participation, keep learning after launch and plan for more than product design.
Key takeaways
Solutions to ensure medical devices and products are designed to support the needs of every person.
Cross-collaboration strategies with payers, providers, stakeholders, regulators and the healthcare system to build deeper engagement with clinical teams.
Best practices to develop deeper engagement with clinical teams to meet your stakeholders' needs.
Start with the end in mind
Chandran opens not with a checklist but with a guidance: understanding comes first. "We need to start with the end in mind and kind of work our way backwards, and that starts with questions." (0:00) She asks the audience to consider what makes people different, what drives healthcare inequities, what role a fact base plays, and what small or big actions can start to make a difference.
As a chronic disease epidemiologist who designs pathways to patient access for Abbott's medical device pipeline, she looks at innovation through several lenses at once: clinical unmet needs, healthcare utility, the environment and the policies that can either accelerate or limit access. The reason, she explains, is resilience. "Well, it's because we need to design technologies that are resilient to the diverse pathways of healthcare delivery that we have, not only in the United States, but around the world." (2:23)
More similar than we are different
While preparing the talk, Chandran interviewed colleagues across product development. The perspective that struck her most came from a clinical development leader who reminded her that humans share far more than divides them. "So I'd like to start today by honoring the fact that we are more similar than we are different." (4:07)
That framing sharpens the central puzzle. If no gene makes someone African American or Indian, why do people of color experience illness and healthcare so differently? As the speaker cited, African Americans have a life expectancy four years lower than white Americans, and although cardiovascular mortality is falling in the United States, African Americans still have the highest rate of death.
Her answer draws on her public health roots: social determinants of health. Where people work and live, their education, access to healthy food, social support, community, culture and engagement with the healthcare system all influence health status and care seeking. Unlike genetics, these factors are driven by policy, culture and society. "But what's most important is that these factors can create systemic inequality. And that systemic inequality disproportionately affects communities of color." (7:38)
Where clinical trials fall short
The industry is good at asking where the biggest unmet needs are, Chandran says. The harder question is whether every patient who needs an intervention will have an equitable pathway to it. Clinical trials are pivotal for proving safety and efficacy to the FDA, yet women and populations of color are systematically underrepresented in them.
She explains how this happens. In medical device studies, costs are often shared by Medicare or commercial insurance, which tilts participation toward insured patients and away from those who are financially disadvantaged. Even with a hardship program, strict protocols filter out people with inflexible work schedules, no caregiver support or no transportation. "So without designing studies that are representative, it's hard for us to say that we are truly addressing the needs of a heterogeneous population." (11:05)
The figures she shares make the gap concrete. As the speaker cited, in 2011 African Americans and Hispanic Americans made up 16 and 12 percent of the US population but only 1 and 5 percent of clinical trial patients. More recently, an FDA review of the 53 new drugs approved in 2020 found that 75 percent of the roughly 32,000 patients involved were white.
Removing barriers and continuing to learn
The opportunities start with the same social determinants. Chandran suggests providing transportation to trial sites, bringing care to patients' homes, investing in education and health literacy, and breaking down cultural barriers. Some communities have good reasons to distrust research, and reaching them takes creative work. "Websites might be helpful, but they are not the only way to engage with communities." (14:27) She points to churches and trusted local partners such as nail salons and barbershops.
Learning should not stop when a trial ends. Real-world evidence shows how patients actually engage with new technologies and where barriers remain. Patients themselves need a voice: "Patient advocacy is an incredibly powerful tool." (15:28) And no single person or group can carry this alone; asking, answering and investing in these questions must become a shared norm.
When that happens, she says, evidence becomes more representative, data sources validate each other, and the industry builds a network of learning that helps it serve people who are underserved today.
Takeaways for any product
Chandran closes with lessons she believes apply whatever the product. Understand your customer and make sure the sample you study represents them. Accept that bias will exist in methods and systems, and address it openly: "We should have an open dialogue around bias and identify ways to compensate for that bias." (18:27) Recognise the limits of design itself: "I think we have to know that we can't always solve for inequity using a design of a technology." (18:52) Finally, plan for continuous improvement and keep asking the questions.
Watch the talk
Healthcare Leaders: Leveraging Data, Emerging MedTech & Collaboration to Meet the Needs of Underserved Communities, Arthi Chandran, 20 minutes: https://www.womentech.net/video/healthcare-leaders-leveraging-data-emerging-medtech-collaboration-meet-needs-underserved
About the speaker
Arthi Chandran is the Divisional Vice President of Health Economics and Reimbursement for Abbott Medical Devices, where she leads a global team of researchers and reimbursement specialists responsible for ensuring patients around the world have an equitable opportunity to benefit from Abbott's technologies. With over 15 years in the MedTech and pharmaceutical industries, she is recognized for embedding value demonstration through differentiated evidence generation strategies and economic tools.
Questions this talk answers
If race is not biological, what explains healthcare disparities between racial groups?
Why are women and people of color underrepresented in medical device trials?
How can companies make clinical trials more representative?
What should happen after a technology reaches the market?
Can good product design alone solve healthcare inequity?
Drafted with AI from the talk transcript. Editor review pending.
Frameworks and ideas mentioned
Social determinants of health
Real-world evidence
Cite this talk
Arthi Chandran. "Healthcare Leaders: Leveraging Data, Emerging MedTech & Collaboration to Meet the Needs of Underserved Communities." WomenTech Network, 2023. https://www.womentech.net/video/healthcare-leaders-leveraging-data-emerging-medtech-collaboration-meet-needs-underserved